DBVT
Strong SellSinkerDBV Technologies S.A. · Healthcare · France · $851M · Avg Vol: $4M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT DBV TECHNOLOGIES S.A.
Read
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing Viaskin, a proprietary epicutaneous immunotherapy platform for the treatment of food allergies. The company aims to address significant unmet medical needs by delivering allergens through the skin, offering a non-invasive approach to desensitize patients. Its competitive moat is built on its innovative Viaskin patch technology and its advanced pipeline targeting conditions like peanut and milk allergies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | 2.7M | 61.9M | — |
| EPS | -8.90 | -6.20 | -3.80 | -5.85 | -20.90 | — | -3.50 | — | — | — |
| Shares | 55.1M | 94.0M | 96.2M | 102.6M | 59.2M | +7.4% | 62.8M | — | — | — |
| Debt | 12.0M | 4.2M | 6.6M | 7.8M | 8.0M | -9.6% | 7.7M | — | — | — |
| Equity | 99.3M | 194.5M | 140.2M | 27.4M | 168.8M | 14.2% | — | — | — | — |
| Op CF | -108.2M | -55.7M | -79.7M | -104.5M | -121.2M | — | -169.3M | — | — | — |
| Inv CF | -0.4M | -0.1M | -0.8M | -0.8M | -1.4M | — | — | — | — | — |
| Fin CF | 0.3M | 194.1M | 6.8M | 0.6M | 276.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DBVT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DBVT | DBV Technologies S.A.(you) | $851M | 8 | Strong Sell |
| IVA | Inventiva S.A. | $1.1B | 8 | Strong Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| VLA.PA | Valneva SE | $614M | 3 | Strong Sell |
| MEDCL.PA | MedinCell S.A. | $1.0B | 21 | Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
| GNFT.PA | Genfit S.A. | $835M | 36 | Hold |
| IPHA | Innate Pharma S.A. | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
Peer medians: ROE -32.6% · P/E 22.9x · Gross margin 69.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.